Photo of Molly Cook
D Texas Senate · District 15

Sen. Molly Cook

Compare
Total votes
5,045
all sessions
Attendance
98%
91 missed
Near the chamber average
With party
72%
of cast votes
Among the lowest in the chamber
Bipartisan score
15%
some cross-party votes
Higher than 96% of chamber peers
Sponsored
10
bills & resolutions
Among the lowest in the chamber
Committees
3
assignments
5,045 roll-call votes

Voting record

Breaks with party 28% of the time

Yea
3,260
voted in favor
Nay
1,694
voted against
Absent
91
missed votes
Total cast
5,045
across all sessions
Crossed party
1,355
votes against own party
This page
5,045
matching current filters
Bill
Description
Vote
Result
Tally
Date
SB 2900
Relating to certain advisory entities and work groups under the jurisdiction of the comptroller of public accounts or on which the comptroller's office is represented and to the repeal or redesignation of certain of those entities. Against party
Nay
Passed
106–28
Jun 1, 2025
HB 40
Relating to the business court. Against party
Yea
Passed
95–38
Jun 1, 2025
HB 40
Relating to the business court.
Nay
Passed
23–7
Jun 1, 2025
SB 2972
Relating to expressive activities at public institutions of higher education.
Nay
Passed
21–9
Jun 1, 2025
HB 2885
Relating to allowing the governing bodies of certain political subdivisions to call for a local option election relating to the sale of alcoholic beverages. Against party
Nay
Passed
100–27
Jun 1, 2025
HB 493
Relating to ineligibility to serve as a poll watcher.
Nay
Passed
22–8
Jun 1, 2025
SB 1540
Relating to maintaining the confidentiality of the personal information of election officials and their employees.
Yea
Passed
127–9
Jun 1, 2025
HR 1523
Suspending limitations on conference committee jurisdiction, H.B. No. 46.
Yea
Passed
127–12
Jun 1, 2025
SB 2217
Relating to certain election practices and procedures.
Yea
Passed
129–6
Jun 1, 2025
SB 2308
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Yea
Passed
133–3
Jun 1, 2025
Showing 211 to 220 of 5,045 votes
Previous 1 21 22 23 505 Next